Logos Global Management as of Dec. 31, 2020
Portfolio Holdings for Logos Global Management
Logos Global Management holds 59 positions in its portfolio as reported in the December 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Alx Oncology Hldgs (ALXO) | 23.3 | $272M | 3.2M | 86.20 | |
| Olema Pharmaceuticals (OLMA) | 15.4 | $180M | 3.7M | 48.08 | |
| Nkarta (NKTX) | 8.9 | $103M | 1.7M | 61.47 | |
| Forma Therapeutics Hldgs SHS | 4.2 | $49M | 1.4M | 34.90 | |
| Tg Therapeutics (TGTX) | 3.8 | $44M | 850k | 52.02 | |
| Dyne Therapeutics (DYN) | 2.9 | $34M | 1.6M | 21.00 | |
| Athira Pharma (ATHA) | 2.8 | $33M | 948k | 34.25 | |
| Keros Therapeutics (KROS) | 2.7 | $32M | 450k | 70.54 | |
| Repare Therapeutics Ord (RPTX) | 2.0 | $23M | 677k | 34.30 | |
| Kinnate Biopharma (KNTE) | 1.9 | $23M | 570k | 39.78 | |
| Cogent Biosciences (COGT) | 1.8 | $22M | 1.9M | 11.23 | |
| Bioxcel Therapeutics (BTAI) | 1.7 | $20M | 430k | 46.20 | |
| Apellis Pharmaceuticals (APLS) | 1.5 | $17M | 300k | 57.20 | |
| Biohaven Pharmaceutical Holding Call Option | 1.5 | $17M | 200k | 85.71 | |
| Avidity Biosciences Ord (RNA) | 1.5 | $17M | 672k | 25.52 | |
| Aligos Therapeutics (ALGS) | 1.4 | $17M | 607k | 27.65 | |
| C4 Therapeutics Com Stk (CCCC) | 1.4 | $16M | 478k | 33.13 | |
| Larimar Therapeutics (LRMR) | 1.3 | $15M | 715k | 21.41 | |
| Compass Pathways Sponsored Ads (CMPS) | 1.2 | $14M | 300k | 47.64 | |
| Silverback Therapeutics (SPRY) | 1.2 | $14M | 300k | 46.34 | |
| Igm Biosciences (IGMS) | 1.1 | $13M | 150k | 88.29 | |
| Karuna Therapeutics Ord | 1.0 | $12M | 120k | 101.59 | |
| Abcellera Biologics (ABCL) | 1.0 | $12M | 300k | 40.24 | |
| Mirati Therapeutics | 0.9 | $11M | 50k | 219.64 | |
| Calliditas Therapeutics Ab Sponsered Ads (CALT) | 0.9 | $10M | 300k | 33.62 | |
| Curis Com New | 0.8 | $9.8M | 1.2M | 8.19 | |
| Kalvista Pharmaceuticals (KALV) | 0.8 | $9.3M | 490k | 18.99 | |
| Miragen Therapeutics Com New | 0.8 | $9.0M | 550k | 16.45 | |
| Passage Bio (PASG) | 0.8 | $8.8M | 344k | 25.57 | |
| Vincera Pharma Unit 12/24/2025 | 0.7 | $7.7M | 400k | 19.26 | |
| Nurix Therapeutics (NRIX) | 0.6 | $7.6M | 230k | 32.88 | |
| Therapeutics Acquisition Cor Com Cl A | 0.6 | $7.0M | 500k | 13.92 | |
| Kymera Therapeutics (KYMR) | 0.6 | $6.9M | 111k | 62.00 | |
| Essa Pharma Com New (EPIX) | 0.6 | $6.6M | 550k | 11.93 | |
| Shattuck Labs (STTK) | 0.5 | $6.4M | 122k | 52.41 | |
| Pmv Pharmaceuticals (PMVP) | 0.5 | $6.2M | 100k | 61.51 | |
| Pulmonx Corp (LUNG) | 0.4 | $5.2M | 75k | 69.03 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.4 | $4.6M | 700k | 6.58 | |
| Annexon (ANNX) | 0.3 | $4.0M | 160k | 25.03 | |
| Black Diamond Therapeutics (BDTX) | 0.3 | $4.0M | 124k | 32.05 | |
| Health Sciences Acq Corp 2 Ord Shs | 0.3 | $3.8M | 300k | 12.81 | |
| Vaxcyte (PCVX) | 0.3 | $3.7M | 140k | 26.57 | |
| Harmony Biosciences Hldgs In (HRMY) | 0.3 | $3.6M | 100k | 36.15 | |
| Bristol-myers Squibb Right 99/99/9999 | 0.3 | $3.5M | 5.1M | 0.69 | |
| Tokai Pharmaceuticals | 0.3 | $3.5M | 224k | 15.40 | |
| Iteos Therapeutics (ITOS) | 0.3 | $3.4M | 100k | 33.82 | |
| Outset Med (OM) | 0.2 | $2.8M | 50k | 56.84 | |
| Panacea Acquisition Corp Unit 99/99/9999 | 0.2 | $2.6M | 200k | 12.76 | |
| Bctg Acquisition Corp | 0.2 | $2.3M | 200k | 11.44 | |
| Helix Acquisition Corp Com Cl A | 0.2 | $2.3M | 200k | 11.37 | |
| Eargo | 0.2 | $2.2M | 50k | 44.82 | |
| Opthea Sponsored Ads (OPT) | 0.2 | $1.8M | 160k | 11.21 | |
| Pliant Therapeutics (PLRX) | 0.1 | $1.7M | 76k | 22.71 | |
| Travere Therapeutics (TVTX) | 0.1 | $1.7M | 61k | 27.26 | |
| Cerevel Therapeutics Hldng I (CERE) | 0.1 | $1.7M | 100k | 16.58 | |
| Applied Molecular Trans | 0.1 | $1.3M | 43k | 30.76 | |
| Fs Dev Corp Com Cl A | 0.1 | $1.1M | 100k | 11.00 | |
| Generation Bio (GBIO) | 0.0 | $482k | 17k | 28.35 | |
| Cerevel Therapeutics Hldng I *w Exp 06/09/202 (CEREW) | 0.0 | $188k | 33k | 5.64 |
